2020
The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).
Gross C, Meyer C, Ogale S, Kent M, Wong W. The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.29_suppl.89.Peer-Reviewed Original ResearchBiomarker-driven therapiesBiomarker testingEvidence of testingYear of diagnosisQuality cancer careUS cancer patientsLikelihood of testingDe-identified databaseEvidence of receiptEligible ptsOverall survivalAdjusted analysisContemporary cohortMedicaid insuranceRetrospective studyCancer careCancer patientsWorse outcomesCancer clinicHigh riskCommercial insurancePrivate insuranceAdvanced diagnosisTherapyDiagnosis
2019
Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment.
Adamson B, Cohen A, Estevez M, Magee K, Williams E, Gross C, Meropol N, Davidoff A. Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. Journal Of Clinical Oncology 2019, 37: lba1-lba1. DOI: 10.1200/jco.2019.37.18_suppl.lba1.Peer-Reviewed Original ResearchTimely treatmentMedicaid expansionRacial disparitiesFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseCancer ptsDiagnosis dateTreatment startAdvanced cancerMetastatic diagnosisCancer outcomesMetastatic cancerState of residenceHealthcare accessAge 18Private insuranceCancer typesExpansion statusTreatment overallCancer treatmentPractice typeTreatmentAfrican AmericansOutcomesCancer